全文获取类型
收费全文 | 3555篇 |
免费 | 220篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 19篇 |
儿科学 | 98篇 |
妇产科学 | 84篇 |
基础医学 | 494篇 |
口腔科学 | 48篇 |
临床医学 | 316篇 |
内科学 | 982篇 |
皮肤病学 | 66篇 |
神经病学 | 436篇 |
特种医学 | 75篇 |
外科学 | 291篇 |
综合类 | 7篇 |
预防医学 | 166篇 |
眼科学 | 90篇 |
药学 | 264篇 |
中国医学 | 5篇 |
肿瘤学 | 374篇 |
出版年
2024年 | 10篇 |
2023年 | 59篇 |
2022年 | 123篇 |
2021年 | 196篇 |
2020年 | 127篇 |
2019年 | 141篇 |
2018年 | 153篇 |
2017年 | 92篇 |
2016年 | 121篇 |
2015年 | 158篇 |
2014年 | 156篇 |
2013年 | 191篇 |
2012年 | 316篇 |
2011年 | 326篇 |
2010年 | 179篇 |
2009年 | 161篇 |
2008年 | 236篇 |
2007年 | 183篇 |
2006年 | 186篇 |
2005年 | 149篇 |
2004年 | 133篇 |
2003年 | 124篇 |
2002年 | 103篇 |
2001年 | 34篇 |
2000年 | 19篇 |
1999年 | 17篇 |
1998年 | 19篇 |
1997年 | 7篇 |
1996年 | 7篇 |
1995年 | 6篇 |
1994年 | 3篇 |
1993年 | 7篇 |
1992年 | 9篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1989年 | 8篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1978年 | 5篇 |
1972年 | 2篇 |
1971年 | 2篇 |
1970年 | 4篇 |
1969年 | 2篇 |
1968年 | 5篇 |
1967年 | 1篇 |
1966年 | 2篇 |
1965年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有3815条查询结果,搜索用时 15 毫秒
51.
52.
Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma
Vanessa?Desantis Maria?Antonia?Frassanito Roberto?Tamma Ilaria?Saltarella Lucia?Di?Marzo Aurelia?Lamanuzzi Antonio?Giovanni?Solimando Simona?Ruggieri Tiziana?Annese Beatrice?Nico Angelo?Vacca Domenico?RibattiEmail authorView authors OrcID profile 《Annals of hematology》2018,97(7):1251-1258
We have previously demonstrated that recombinant human erythropoietin (rHuEpo) is involved in the regulation of the angiogenic response in multiple myeloma (MM) through a direct effect on macrophages and endothelial cells isolated from the bone marrow of patients with MM. The aim of the present study was designed to determine the effects of rHuEpo on cancer-associated fibroblasts (CAFs) from monoclonal gammopathy of undetermined significance (MGUS) and MM patients by means of in vitro and in vivo assays. rHuEpo treatment reduces the expression of mRNA levels of fibroblast activation markers, namely alpha smooth actin (αSMA) and fibroblast activation protein (FAP) in MGUS and MM CAFs, and of pro-inflammatory and pro-angiogenic cytokines, including interleukin (IL)-6 and IL-8, vascular endothelial growth factor-A (VEGF-A), fibroblast growth factor-2 (FGF-2), and hepatocyte growth factor (HGF) in MM CAFs. Moreover, rHuEpo inhibits the proliferative activity of MM CAFs and increased the apoptosis of MGUS and MM CAFs. Overall, these data suggest that rHu-Epo down-regulates CAFs pro-tumorigenic activity. Moreover, these results are not suggestive for a pro-angiogenic activity of rHuEpo on CAFs. In fact, rHuEpo pre-treatment induces a low angiogenic response in vivo in the chorioallantoic membrane (CAM) assay of MGUS and MM CAFs conditioned medium, not comparable to that of a well-known angiogenic cytokine, VEGF-A, tested in the same assay. 相似文献
53.
Depression and cancer: an unexplored and unresolved emergent issue in elderly patients 总被引:1,自引:0,他引:1
Spoletini I Gianni W Repetto L Bria P Caltagirone C Bossù P Spalletta G 《Critical reviews in oncology/hematology》2008,65(2):143-155
Despite the high prevalence of depressive disorders in cancer patients and elderly people, the topic of depression in elderly cancer patients still remains unexplored. This emerges from a systematic review of the literature conducted to investigate issues of depression, diagnosis, pathogenesis, treatment and their complex neuroimmunobiological interactions. Indeed, it becomes apparent that depression in elderly patients with cancer may have a peculiar phenomenology. In addition, the moderate rate of major depressive disorder and the high rate of minor depressive disorder are accompanied by subthreshold forms of depression that are at risk to be underrecognized and untreated. Immune dysfunction may represent a common pathogenic ground of depression, cancer and aging. This may have important implications for treatment. In the near future, we need to develop validated mood disorder diagnoses and verify antidepressant treatment efficacy for elderly cancer patients with depression in order to improve their clinical outcome and quality of life. 相似文献
54.
Endothelial Dysfunction in Early Systemic Lupus Erythematosus Patients and Controls Without Previous Cardiovascular Events 下载免费PDF全文
Mara Taraborelli Edoardo Sciatti Ivano Bonadei Vincenzo Terlizzi Micaela Fredi Roberta Zani Giovanni Cancarini Angela Tincani Franco Franceschini Enrico Vizzardi Ilaria Cavazzana 《Arthritis care & research》2018,70(9):1277-1283
Objective
To assess the prevalence and risk factors for endothelial dysfunction detected by peripheral artery tonometry in systemic lupus erythematosus patients with early disease without cardiovascular disease and risk factors.Methods
All the consecutive adult lupus patients, with a disease duration <5 years, seen in our hospital from December 2014 to March 2016 were considered. We excluded patients with any history of cardiovascular disease or risk factors possibly affecting peripheral artery tonometry. Enrolled patients were matched for sex, age, body mass index, and blood pressure with healthy controls with the same exclusion criteria. Patients and controls received a transthoracic Doppler echocardiogram and an evaluation of endothelial function by peripheral artery tonometry.Results
Twenty patients (100% female) with a median disease duration of 14 months (range 1–58 months), a mean ± SD age of 42 ± 15 years, and a mean ± SD age at diagnosis of 40 ± 16 years were enrolled and matched with 20 controls. Peripheral artery tonometry showed a significantly higher prevalence of endothelial dysfunction (P = 0.003) and vascular stiffness (P = 0.02), while echocardiography detected a significantly higher prevalence of left ventricular concentric remodeling (P = 0.003), grade I diastolic dysfunction (P = 0.047), and subclinical increase of filling pressures (P = 0.039) in lupus patients compared to controls. Among lupus patients, no features were associated with endothelial dysfunction.Conclusion
A high rate of endothelial dysfunction and vascular stiffness occurs in early lupus patients without cardiovascular risk factors and disease. Larger studies are needed to confirm our results and to look for patients’ characteristics possibly associated with these abnormalities.55.
56.
57.
Stefano Sansone Maria Guarino Fabiana Castiglione Antonio Rispo Francesco Auriemma Ilaria Loperto Matilde Rea Nicola Caporaso Filomena Morisco 《World journal of gastroenterology : WJG》2014,20(13):3516-3524
In recent years,a number of case reports and clinical studies have highlighted the risk of hepatitis B and C virus reactivation in patients with inflammatory bowel disease who are treated with immunosuppressive drugs.The cases of viral hepatitis reactivation that have been reported are characterized by a wide range of clinical manifestations,from viremia without clinically relevant manifestations to fulminant life-threatening hepatitis.The development and dissemination of biological immunosuppressive drugs have led to a significant increase in the number of reports of interest to physicians in a variety of clinical settings.On this topic,there have been a number of published guidelines and reviews that have collected the available evidence,providing recommendations on prophylactic and therapeutic strategies and methods for monitoring patients at risk.However,it should be noted that,to date,very few clinical studies have been published,and most of the recommendations have been borrowed from otherclinical settings.The published studies are mostly retrospective and are based on very heterogeneous populations,using different therapeutic and prophylactic regimens and obtaining conflicting results.Thus,it seems clear that it is desirable to concentrate our efforts on prospective studies,not conducting further reviews of the literature in the continued absence of new evidence. 相似文献
58.
59.
Antonelli A Ferrari SM Frascerra S Ruffilli I Pupilli C Bernini G Sellari-Franceschini S Gelmini S Ferrannini E Fallahi P 《The Journal of endocrinology》2012,213(2):183-191
No data are present in the literature about the effect of cytokines on the prototype β chemokine (C-C motif) ligand 2 (CCL2) or of peroxisome proliferator-activated receptor α (PPARα (PPARA)) activation on CCL2 and CXCL10 chemokines secretion in fibroblasts or preadipocytes in Graves' ophthalmopathy (GO). We have tested the effect of interferon γ (IFNγ (IFNG)) and tumor necrosis factor α (TNFα) on CCL2, and for comparison on the prototype α chemokine (C-X-C motif) ligand 10 (CXCL10), and the possible modulatory role of PPARα activation on secretion of these chemokines in normal and GO fibroblasts or preadipocytes in primary cell cultures. This study shows that IFNγ alone, or in combination with TNFα, stimulates the secretion of CCL2 in primary orbital fibroblasts or preadipocytes from patients with GO at levels similar to those observed in controls. IFNγ and TNFα also stimulated CXCL10 chemokine secretion as expected. The presence of PPARα and PPARγ (PPARG) in primary fibroblasts or preadipocytes of patients with GO has been confirmed. PPARα activators were able to inhibit the secretion of CXCL10 and CCL2, while PPARγ activators were confirmed to be able to inhibit CXCL10 but had no effect on CCL2. PPARα activators were stronger inhibitors of chemokine secretions than PPARγ agonists. In conclusion, CCL2 and CXCL10 are modulated by IFNγ and TNFα in GO. PPARα activators inhibit the secretion of the main prototype α (CXCL10) and β (CCL2) chemokines in GO fibroblasts or preadipocytes, suggesting that PPARα may be involved in the modulation of the immune response in GO. 相似文献
60.
Nicolucci A Balducci S Cardelli P Cavallo S Fallucca S Bazuro A Simonelli P Iacobini C Zanuso S Pugliese G;Italian Diabetes Exercise Study Investigators 《Diabetologia》2012,55(3):579-588